8-K: BioAffinity Technologies Faces Nasdaq Delisting Threat Over Sub-Minimum Stockholders' Equity

BioAffinity Technologies, Inc. has received a notice from Nasdaq regarding non-compliance with the minimum stockholders' equity requirement, potentially jeopardizing its continued listing.

Summary

• BioAffinity Technologies, Inc. (BIAF) received a notice from Nasdaq on May 27, 2025, indicating non-compliance with Nasdaq Listing Rule 5550(b)(1) due to insufficient stockholders' equity.
• As of March 31, 2025, the company's stockholders' equity was $1,439,404, which is below the Nasdaq minimum requirement of $2,500,000.
• The company also does not meet the alternative quantitative standards for continued listing, including a market value of listed securities of $35 million or net income from continued operations of $500,000.
• This notification does not immediately affect the company's listing, and its common stock will continue to trade on The Nasdaq Capital Market under the symbol BIAF.
• BioAffinity Technologies has 45 calendar days, until July 11, 2025, to submit a plan to regain compliance.
• If the compliance plan is accepted, the company may be granted an extension of up to 180 calendar days from May 27, 2025, to regain compliance.
• This issue is in addition to a previously disclosed deficiency letter from February 7, 2025, regarding the company's failure to maintain a minimum bid price of $1.00 per share.

Sentiment

Score: 3

Explanation: The document indicates significant financial distress and regulatory non-compliance, with the company failing to meet multiple Nasdaq listing requirements, including stockholders' equity and minimum bid price. This poses a substantial risk of delisting, which is highly negative for investors.

Positives

• The notification has no immediate effect on the company's continued listing on the Nasdaq Capital Market.
• The company's common stock will continue to trade on Nasdaq under the symbol BIAF, subject to compliance with other listing requirements.
• The company has a defined period (45 days) to submit a compliance plan and a potential extension (180 days) if the plan is accepted.

Negatives

• The company's stockholders' equity of $1,439,404 as of March 31, 2025, is significantly below Nasdaq's minimum requirement of $2,500,000.
• BioAffinity Technologies does not meet the alternative Nasdaq listing standards, including a $35 million market value of listed securities or $500,000 in net income from continued operations.
• This non-compliance is in addition to a previously disclosed deficiency regarding the failure to maintain a minimum bid price of $1.00 per share.
• Failure to regain compliance could lead to delisting from Nasdaq.

Risks

• Risk of delisting from The Nasdaq Capital Market if the company fails to submit an acceptable compliance plan or does not regain compliance within the specified extension period.
• Uncertainty regarding the acceptance of the company's compliance plan by Nasdaq.
• Potential for further action by Nasdaq if the company fails to meet the minimum bid price requirement, which is a separate, ongoing deficiency.
• Impact on investor confidence and stock liquidity due to ongoing listing compliance issues.

Future Outlook

BioAffinity Technologies intends to submit a compliance plan within the required 45-day period, monitor its stockholders' equity, and consider further available options to regain compliance with the Nasdaq Stockholders' Equity Requirement. There is no assurance that the compliance plan will be accepted or that the company will regain compliance within any granted extension period.

Management Comments

• "The Company intends to submit a Compliance Plan within the required time, monitor its stockholders equity and, if appropriate, consider further available options to regain compliance with the Stockholders Equity Requirement, although there can be no assurance that the Compliance Plan will be accepted by Nasdaq."

Industry Context

For a biotechnology company like bioAffinity Technologies, maintaining a Nasdaq listing is crucial for access to capital markets, investor visibility, and perceived credibility. Failure to meet listing standards, particularly related to financial health like stockholders' equity, can severely impact a company's ability to fund research and development, attract talent, and compete effectively. Delisting often leads to reduced liquidity and investor interest, potentially forcing a move to over-the-counter markets, which are less regulated and less attractive to institutional investors.

Comparison to Industry Standards

• BioAffinity Technologies' stockholders' equity of $1,439,404 is significantly below the Nasdaq Capital Market's minimum requirement of $2,500,000, indicating a financial position weaker than the baseline expected for listed companies.
• The company also fails to meet alternative Nasdaq listing standards, such as a $35 million market value of listed securities or $500,000 in net income from continued operations, further highlighting its non-compliance with standard financial benchmarks for public companies.
• The ongoing issue with the minimum bid price requirement ($1.00 per share) suggests a sustained period of underperformance relative to typical stock price stability expected of Nasdaq-listed entities.

Stakeholder Impact

• Shareholders: Face increased risk of delisting, which could lead to reduced stock liquidity, lower stock price, and potential transfer to less liquid over-the-counter markets.
• Employees: Potential uncertainty regarding the company's long-term stability and ability to raise capital for operations.
• Creditors: May view the company as a higher credit risk due to financial instability and potential delisting.
• Customers/Partners: Could perceive the company as less stable, potentially impacting business relationships.

Next Steps

• BioAffinity Technologies must submit a compliance plan to Nasdaq by July 11, 2025.
• The company will monitor its stockholders' equity.
• The company will consider further available options to regain compliance.
• If the compliance plan is accepted, the company will have up to 180 calendar days from May 27, 2025, to regain compliance.
• If the plan is not accepted or compliance is not regained, the company has the right to a hearing before Nasdaq's Hearing Panel.

Key Dates

Recommendation

Keywords

bioAffinity Technologies, BIAF, Nasdaq, Delisting, Stockholders' Equity, Listing Rules, Form 8-K, Compliance Plan, Minimum Bid Price, Biotechnology, SEC Filing